At MabVax Therapeutics Holdings, Inc., we are advancing a pipeline of human monoclonal antibody products that are based on the protective immune responses generated by patients who have been immunized against targeted cancers with our proprietary vaccines.

• We plan to initiate a Phase 1 clinical trial in early 2016 with our lead fully human antibody candidate HuMab 5B1 as a therapeutic treatment for metastatic pancreatic cancer.

• We plan to initiate a Phase 1 clinical trial in early 2016 with our HuMab 5B1-based companion diagnostic product as a next-generation PET imaging agent for the diagnosis and treatment assessment of metastatic pancreatic cancer.

• We have a Phase 2-ready therapeutic cancer vaccine for the childhood cancer neuroblastoma with plans to enter the clinic in 2016. Our vaccine has been granted Orphan Drug Designation by the FDA.

• We have a robust antibody discovery platform with multiple fully developed human antibody leads to 11 targets. Our leads are developed from our exclusive license with Memorial Sloan Kettering Cancer Center.

• Members of our executive management team and board of directors all have significant experience in the development of drugs and diagnostics.

>Read More about MabVax Therapeutics

MabVax Therapeutics to Hold Investor Webcast and Conference Call on Thursday October 22nd at 11:00am EDT

Read More >

To Access the Live Webcast with Illustrative Slides CLICK HERE


October 15, 2015
MabVax Therapeutics Announces License Agreement for Cell Line to Produce HuMab 5B1 for Phase I Clinical Trials
Read More >

October 8, 2015
OPKO Health, Inc. Participates in latest round of financing for MabVax Therapeutics.
Read More >

September 30, 2015
MabVax Therapeutics Holdings, Inc. Announces Pricing of Public Offering.
Read More >

August 31, 2015
MabVax Therapeutics HuMab 5B1 Antibody is highlighted in upcoming World Molecular Imaging Congress. 
Read More>

July 31, 2015
MabVax Releases 2015 Shareholder Letter  
Read More >

July 1, 2015
MabVax Therapeutics Holdings Obtains Release of $3.5 Million in Escrowed Funds  
Read More >

HuMab 5B1 Program 

Shareholder Letter 

Fact Sheet 

Corporate Presentation 

   Sign up for Email Alerts

Be the first to get breaking news 


 Shareholder Letter: 

2015 MabVax Shareholder Letter.pdf 2015 MabVax Shareholder Letter.pdf
Size : 170.929 Kb
Type : pdf

Investor Presentation: 

MabVax Investor Presentation September 2015.pdf MabVax Investor Presentation September 2015.pdf
Size : 7747.416 Kb
Type : pdf


Loading data...
MabVax Therapeutics

Contact Us: MabVax Therapeutics
 11588 Sorrento Valley Road Suite 20
San Diego, California, 92121   (858) - 259 - 9405
email: info@mabvax.com

  © 2015, MabVax Therapeutics. All Rights Reserved 
Privacy Policy     Terms of Use     Disclaimer     Sitemap